Results about: patients
An international consortium identifies the breast cancer patients who would benefit from a treatment to prevent metastasis
A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.
This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.
Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.
In EMBO Molecular Medicine, IRB Barcelona scientists report a technique based on a combination of CRISPR/Cas9 genome editing and patient-derived tumour organoids that allows the study of cell heterogeneity in human tumours.
The novel approach was used to examine the behaviour of colorectal cancer stem cells by tracing specific marker genes.
Researchers at IDIBAPS and IRB Barcelona have described in Cancer Research, that the longer the time from the onset of the tumour to the development of metastasis is, the more aggressive this cancer becomes.